February 9, 2018 / 11:42 AM / 6 months ago

BRIEF-Novo Nordisk Says Diabetes Drug Ozempic Has Been Approved In The EU

Feb 9 (Reuters) - NOVO NORDISK:

* OZEMPIC (SEMAGLUTIDE) APPROVED IN EU FOR TREATMENT OF TYPE 2 DIABETES​

* SAYS ‍OZEMPIC HAS BEEN APPROVED IN EU FOR USE IN A MULTI-DOSE PEN, HOWEVER, NOVO INTENDS TO SUBMIT A VARIATION APPLICATION TO EUROPEAN MEDICINES AGENCY (EMA) SEEKING APPROVAL OF AN UPDATED OZEMPIC PEN OFFERING

* OZEMPIC WAS APPROVED BY THE U.S. FDA ON 5 DECEMBER 2017 SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE: (Reporting by Stine Jacobsen)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below